Literature DB >> 29307459

Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure.

Yitschak Biton1, Spencer Rosero2, Arthur Moss2, Wojciech Zareba2, Valentina Kutyifa2, Jayson Baman3, Alon Barsheshet4, Scott McNitt2, Bronislava Polonsky2, Ilan Goldenberg5.   

Abstract

The ACC/AHA/HRS (American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society) guidelines recommend implantable cardioverter-defibrillator (ICD) therapy primary prevention in all patients with severely reduced left ventricular ejection fraction (≤30%) regardless of New York Heart Association (NYHA) functional class, whereas recent European guidelines limit the indication to those with symptomatic heart failure (NYHA ≥ II). We therefore aimed to evaluate the long-term survival benefit of primary ICD therapy among postmyocardial infarction patients with and without heart failure (HF) symptoms who were enrolled in MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II). We classified 1,164 MADIT-II patient groups according to the baseline NYHA class (NYHA I [n = 442], NYHA II [n = 425], and NYHA III [n = 297]); patients with NYHA IV were excluded. Multivariate Cox proportional hazards regression modeling was performed to compare the mortality reduction with ICD versus non-ICD therapy during 8 years of follow-up between the 3 NYHA groups. The median (interquartile range) follow-up time was 7.6 (3.5 to 9) years. At 8 years of follow-up, the cumulative probability of mortality in the non-ICD treatment arm was 57% for NYHA I, 57% for NYHA II, and 76% for NYHA III (p <0.001). Multivariate models demonstrated similar long-term mortality risk reduction with ICD compared with the non-ICD treatment arm regardless of HF symptoms: NYHA I (HR = 0.63, 0.46 to 0.85, p = 0.003), NYHA II (HR = 0.68, 0.50 to 0.93, p = 0.017), and NYHA III (HR = 0.68, 0.50 to 0.94, p = 0.018); p for NYHA class by treatment arm interaction >0.10. In conclusion, primary ICD therapy provides consistent long-term survival benefit among patients with previous myocardial infarction and severe left ventricular dysfunction, regardless of HF symptoms.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29307459     DOI: 10.1016/j.amjcard.2017.11.032

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.

Authors:  Mohamad El Moheb; Johny Nicolas; Assem M Khamis; Ghida Iskandarani; Elie A Akl; Marwan Refaat
Journal:  Cochrane Database Syst Rev       Date:  2018-12-08

Review 2.  Who Benefits From a Defibrillator-Balancing the Risk of Sudden Versus Non-sudden Death.

Authors:  Simon A S Beggs; Roy S Gardner; John J V McMurray
Journal:  Curr Heart Fail Rep       Date:  2018-12

3.  Cardio-microcurrent device for chronic heart failure: first-in-human clinical study.

Authors:  Dragana Kosevic; Dominik Wiedemann; Petar Vukovic; Velibor Ristic; Julia Riebandt; Una Radak; Kersten Brandes; Peter Goettel; Hans-Dirk Duengen; Elvis Tahirovic; Tatjana Kottmann; Hans Werner Voss; Marija Zdravkovic; Svetozar Putnik; Jan D Schmitto; Johannes Mueller; Jesus Eduardo Rame; Miodrag Peric
Journal:  ESC Heart Fail       Date:  2021-02-09

4.  The role of implantable cardioverter-defibrillators in New York Heart Class I heart failure patients: do not abandon the asymptomatic just yet.

Authors:  Anne-Lotte C J van der Lingen; Cornelis P Allaart
Journal:  Eur Heart J       Date:  2020-06-01       Impact factor: 29.983

5.  Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators.

Authors:  Nikhil A Mehta; Nashwa Abdulsalam; Ruth Kouides; Hamdy Ahmed; Raisa Atif; Abrar Shah; Sarah Taylor; Dmitry Chuprun; David Huang; Mohan Rao
Journal:  Clin Cardiol       Date:  2019-12-20       Impact factor: 2.882

6.  Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy.

Authors:  Sem Briongos-Figuero; Alvaro Estévez; M Luisa Pérez; José B Martínez-Ferrer; Enrique García; Xavier Viñolas; Ángel Arenal; Javier Alzueta; Roberto Muñoz-Aguilera
Journal:  ESC Heart Fail       Date:  2019-12-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.